Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller exercised stock options and sold shares in a planned transaction. On April 30, 2026, she sold 1,082 Class A common shares at a weighted average price of $99.57 and 4,418 shares at a weighted average price of $99.13 in open-market sales.
On the same date, she exercised options to acquire 5,500 Class A common shares at an exercise price of $6.89 per share from a fully vested option grant. After these transactions, she directly holds 59,634 Class A common shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported an exercise-and-sell transaction in Class A Common Stock. On April 29, 2026, she exercised 5,500 stock options at $27.85 per share and sold 5,500 shares in multiple open‑market trades around the $99–$101 range. After these transactions, she directly held 63,617 shares of Class A Common Stock. The filing notes the trades were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 18, 2024, indicating the timing was set in advance.
NUVL listed a Form 144 notice to sell 16,500 shares of Common Stock. The filing states the shares relate to an exercise of stock options and lists an aggregate value of $1,635,150.00. The filing also records two recent 10b5-1 sales of 5,500 shares each on 03/26/2026 and 02/26/2026. Shares outstanding are shown as 73,181,747 as of 04/30/2026.
Nuvalent, Inc. is holding its 2026 annual meeting of stockholders virtually on June 16, 2026, at 2:00 p.m. Eastern Time. Holders of 73,542,756 shares of Class A common stock as of April 20, 2026 may vote online using a 16-digit control number.
Stockholders will vote on electing two Class II directors, an advisory “say‑on‑pay” resolution covering named executive officer compensation, and ratifying KPMG LLP as independent auditor for 2026. The proxy also highlights 2025 progress, including FDA filings for zidesamtinib and neladalkib and a $500 million public offering.
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish exercised stock options and sold shares in a planned transaction. On April 9, 2026, he exercised options to acquire 3,093 shares of Class A common stock at an exercise price of $27.85 per share.
That same day, he sold 2,193 shares at a weighted average price of $104.27 and 900 shares at a weighted average price of $105.00 under a Rule 10b5-1 trading plan adopted on December 11, 2025. After these transactions, he held 65,604 shares of Class A common stock directly.
Nuvalent, Inc. President and CEO James Richard Porter reported an exercise-and-sell transaction involving company stock. He exercised stock options covering 13,714 shares of Class A Common Stock at an exercise price of $18.93 per share and 16,286 shares at $27.85 per share, acquiring 30,000 shares in total. On the same date, he sold 30,000 shares of Class A Common Stock in open-market transactions at prices reported as $103.21, $103.78, $104.78 and $105.60 per share. According to a footnote, these sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2025. Following the transactions, he directly held 324,879 shares of Nuvalent Class A Common Stock.
Nuvalent, Inc. reported that on April 7, 2026 it announced submitting a New Drug Application to the U.S. Food and Drug Administration for neladalkib. The application covers use in tyrosine kinase inhibitor pre-treated, advanced ALK-positive non-small cell lung cancer.
This step moves neladalkib from clinical development into formal regulatory review, an important stage toward potential U.S. market availability if the FDA later approves the drug.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom exercised stock options for 11,430 shares of Class A common stock at an exercise price of $1.08 per share. On the same date, she sold 11,430 shares in open-market transactions at weighted average prices between $103.81 and $106.69.
The filing shows these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating the sales were scheduled in advance. Following the transactions, Balcom directly holds 85,533 shares of Nuvalent Class A common stock.
Nuvalent, Inc. reported that officer Benjamin Lane received new equity-based compensation. On April 1, 2026, Lane was granted a stock option for 19,000 shares of Class A common stock at an exercise price of $105.64 per share, expiring in 2036. He also received 9,500 shares of Class A common stock in the form of restricted stock units, which vest in three equal annual installments starting after April 1, 2026, subject to continued service. Following the RSU grant, Lane directly holds 50,368 shares of Class A common stock.